GLP-1 Therapy
60 articles on GLP-1 Therapy, written by Shotlee and medically reviewed for clinical accuracy.
People Taking GLP-1 Weight Loss Drugs Like Ozempic and Wegovy Started Moving Less
New data presented at ENDO 2026 reveals a paradox: patients on GLP-1 medications like Ozempic and Wegovy reduced their physical activity despite losing weight.
8 min read
Popular Weight-Loss Drugs Ozempic and Wegovy May Slow Biological Aging
A new clinical trial suggests that semaglutide, the active ingredient in Ozempic and Wegovy, may help slow biological processes associated with aging in adults with HIV.
8 min read
Wegovy Weight Loss Pill Warning: Make Three Changes Now
The new oral Wegovy formulation has arrived, but hair shedding concerns remain. Discover the science behind the risk and three actionable lifestyle changes to protect your hair health while on semaglutide.
8 min read
GLP-1 Weight-Loss Drugs Linked to Lower Risks of Addiction and Overdose
Explore the groundbreaking research linking GLP-1 medications, including Ozempic, Wegovy, Mounjaro, and Zepbound, to a reduced risk of substance use disorders and fewer addiction-related emergencies.
8 min read
Bariatric Surgery Shows 5x More Weight Loss Than GLP-1s in Real-World Study
A groundbreaking real-world comparison study presented at the ASMBS 2025 Annual Scientific Meeting found that bariatric surgery resulted in approximately five times more weight loss compared to popular GLP-1 receptor agonist medications over a two-year period. This research highlights important considerations for patients and healthcare providers navigating weight management options.
7 min read
Managing Ozempic and Wegovy Weight Loss Side Effects: Nausea and Beyond
New research is shedding light on how GLP-1 medications, including popular drugs like Ozempic and Wegovy, influence brain pathways that control nausea, thirst, and reward-driven behaviors. This article delves into these findings and discusses potential strategies for managing common side effects.
7 min read
Most People Who Stop GLP-1 Drugs Like Ozempic Eventually Restart Treatment
A recent study presented at ENDO 2026 sheds light on the patterns of GLP-1 medication use for type 2 diabetes, revealing that while many patients stop treatment, a substantial number later restart, suggesting a more cyclical rather than permanent discontinuation.
7 min read
Novo Nordisk's Semaglutide Implant Could Replace Ozempic Injections
Novo Nordisk and Vivani Medical are developing a semaglutide implant that could eliminate the need for weekly injections. Here is everything to know about the technology.
6 min read
Wegovy and the Wedding Dress: The Hidden Costs of Rapid Weight Loss
Prescription weight loss drugs are becoming a wedding staple, but medical experts warn of serious side effects and ethical concerns behind the trend.
9 min read
Semaglutide Supply Chain Halted: What Dr. Reddy's API Issue Means for You
Dr. Reddy's Laboratories has paused semaglutide shipments due to active ingredient quality concerns. Here is a deep dive into the impact on the GLP-1 market and patient care.
7 min read
Ozempic & Wegovy Safety: The Yale Study on Online Prescribing
A recent JAMA study reveals significant gaps in medical oversight for online GLP-1 prescriptions. Discover the risks and how to ensure safe access to weight loss medications.
7 min read
Beyond the Hype: Understanding GLP-1s and Weight Management
The rise of GLP-1 medications has revolutionized weight management. This comprehensive guide delves into semaglutide, tirzepatide, and other peptide therapies, offering insights into their efficacy, potential side effects, and how to track your progress effectively.
7 min read
Beyond Weight Loss: How GLP-1s Like Ozempic May Reshape Your Inner World
GLP-1 medications have revolutionized weight loss, but are they also changing how we feel, think, and connect? This article delves into the emerging 'Ozempic Personality' and the science behind potential mood and behavioral shifts.
9 min read
Ozempic, Wegovy & Mounjaro: What Your Bones & Joints Need to Know
Millions are experiencing significant weight loss with GLP-1 medications. But what happens to your bones, joints, and muscles as the pounds drop? An orthopedic surgeon shares crucial insights.
7 min read
GLP-1 Regain Risk: Why Weight Loss Benefits Fade Fast After Stopping
A significant new meta-analysis highlights a critical challenge for individuals using GLP-1 medications like Semaglutide and Tirzepatide: rapid weight regain upon cessation. Researchers suggest obesity requires chronic management, similar to other long-term conditions.
6 min read
Medicare's $50 GLP-1 Weight Loss Drug Trial: Who Qualifies?
For many older Americans, the high cost of GLP-1 weight loss medications has been a significant barrier. Now, a new Medicare trial offers a lifeline, potentially making these life-changing drugs accessible for just $50 a month. This article breaks down what you need to know about the Medicare GLP-1 Bridge program, including who qualifies, which medications are covered, and the program's future.
8 min read
Beyond the Scale: How GLP-1s Are Reshaping Women's Social and Career Fortunes
Discover how GLP-1 medications are impacting more than just physical health, influencing career opportunities and personal relationships for women in a remarkable new study.
7 min read
Svemia Approved: What Canada's New Semaglutide Generic Means for You
Canada's Health Department has cleared Apotex's Svemia, marking a major milestone for generic semaglutide availability and weight loss treatment access.
7 min read
Navigating Medicare's New Path for GLP-1 Weight Loss Coverage
For years, Medicare coverage for GLP-1 medications like Ozempic and Wegovy was strictly limited to diabetes management. A significant shift is underway, however, as a new 'Bridge' program opens doors for weight loss coverage, albeit with specific requirements and nuances that patients must navigate.
6 min read
Beyond the Scale: Navigating GLP-1s for Older Adults
As GLP-1 medications become more accessible, older adults are asking: 'Am I too old?' This guide explores the nuances of using these powerful drugs for weight loss in seniors, emphasizing health over age.
7 min read
Wegovy and Ozempic: The Critical Question to Prevent Weight Regain
Discover the single most important question to ask before starting GLP-1 medications like Ozempic or Wegovy. Learn how to ensure sustainable weight loss and avoid the common pitfalls of viewing these drugs as a magic cure.
8 min read
Mounjaro Access Expands: Northern Ireland Launches New Weight Loss Service
Northern Ireland is set to launch a £5 million Regional Obesity Management Service, improving access to Mounjaro and lifestyle support for adults struggling with obesity.
8 min read
GLP-1s and Menopause: Expert Warns of Accelerated Bone Loss Risk
The collision of rapid weight loss driven by GLP-1 medications like Wegovy and Mounjaro with the natural bone density decline of menopause creates a significant, under-discussed risk for women's skeletal health.
6 min read
Ozempic, Wegovy & Mounjaro: How GLP-1s Are Reshaping the Diet Industry
The landscape of weight loss and diet trends is undergoing a seismic shift, largely driven by the widespread adoption of GLP-1 receptor agonists. From Ozempic to Wegovy and Mounjaro, these medications are not just changing how individuals manage their weight but are fundamentally altering the food industry and the very concept of dieting.
7 min read
Ozempic, Wegovy, Mounjaro: Your Health Journey & What to Track
The rise of GLP-1 medications like Ozempic, Wegovy, and Mounjaro has revolutionized weight management and metabolic health for millions. But beyond the prescription, embarking on this journey requires mindful tracking of your progress, symptoms, and overall well-being. This guide explores what you should be paying attention to, offering practical insights for both patients and the natural health industry.
7 min read
Oral Wegovy in the UK: A New Era for Weight Management
Novo Nordisk's groundbreaking approval of an oral GLP-1 for weight management in the UK marks a significant shift, promising wider accessibility and influencing consumer markets.
6 min read
Beyond the Headlines: Unpacking the Real GLP-1 Weight Loss Race
The booming GLP-1 market for weight loss is often simplified by headline prescription numbers. This article delves deeper, examining the complex factors influencing the success of drugs like Wegovy, Zepbound, and Mounjaro, and what they mean for patients and the industry.
8 min read
Beyond the Rx: Mastering Metabolic Health with or Without GLP-1s
GLP-1 medications have revolutionized weight loss and diabetes management, but true metabolic health hinges on sustainable lifestyle changes. Discover how to improve your health, with or without these powerful tools.
7 min read
Beyond Ozempic: Why Zepbound Might Be the Heavyweight Champion for Weight Loss
A comprehensive review of the latest clinical data comparing Tirzepatide, Semaglutide, and Liraglutide to determine the most effective option for significant weight reduction.
8 min read
Semaglutide and Tirzepatide: The Reality of Stopping and Restarting
A groundbreaking analysis of diabetes medication patterns reveals that stopping isn't always permanent. Discover which drugs have the best retention rates and how insurance impacts access.
7 min read
Ozempic and Testosterone: Does Weight Loss Drive Sperm Quality Gains?
A comprehensive review of clinical trials suggests that GLP-1 medications may offer reproductive benefits for men with obesity-related low testosterone, potentially surpassing traditional hormone replacement therapies.
7 min read
Ozempic and Male Fertility: Can Semaglutide Boost Sperm Quality?
Emerging research indicates that GLP-1 medications, including Ozempic and Mounjaro, may offer unexpected benefits for male reproductive health by addressing underlying metabolic issues.
7 min read
Semaglutide and Male Fertility: New Study Reveals Testosterone Boost
Can GLP-1 medications like Ozempic or Wegovy improve male fertility? A new study indicates potential benefits for testosterone and sperm health, but what does this mean for patients?
7 min read
Semaglutide and Blood Pressure Meds: Why Dizziness Risk Is Rising
A new study reveals a potential safety concern when combining GLP-1 medications with blood pressure drugs, highlighting the importance of monitoring hypotensive episodes in select patients.
8 min read
Beyond the Scale: GLP-1 Users & the Exercise Paradox
While GLP-1 medications have revolutionized weight loss, a recent study indicates a concerning trend: users may be reducing their physical activity. This article explores the findings and emphasizes the continued importance of exercise.
7 min read
Ozempic, Wegovy & Mounjaro: Navigating Dizziness and Fainting Risks
Recent research highlights a potential safety concern with GLP-1 medications, linking them to an increased risk of dizziness and fainting, particularly in certain patient groups. Discover what this means for your health.
6 min read
GLP-1 Revolution in India: Affordability Meets Accessibility in Obesity Fight
The advent of affordable, locally produced GLP-1 agonists in India marks a significant shift in managing the nation's escalating obesity crisis. For millions like Manoj, these once exclusive medications are now within reach, provided they adhere to strict medical guidance and lifestyle adjustments.
6 min read
GLP-1s & Telehealth: Navigating Risks and Ensuring Safety
The booming popularity of GLP-1 medications for weight loss has coincided with a dramatic rise in telehealth services. This article delves into the benefits and significant risks of obtaining these powerful drugs online, highlighting critical safety concerns and offering guidance for patients.
6 min read
Beyond Weight Loss: The Next Wave of GLP-1 Drugs
The revolutionary GLP-1 medications have transformed weight management, but the journey of innovation continues. Discover how upcoming drugs aim to enhance patient experience and outcomes.
7 min read
Oral Wegovy's Record-Breaking Launch: The New Era of Needle-Free Weight Loss
Novo Nordisk's Wegovy oral formulation has achieved unprecedented prescription rates, marking a pivotal shift in obesity care and intensifying competition with Eli Lilly.
8 min read
Wegovy Pill Launch: Why 80% of Patients Are Choosing Oral Semaglutide
The launch of the Wegovy pill marks a pivotal shift in obesity treatment. With 80% of new users being first-time patients, oral semaglutide is overcoming historical barriers to care.
9 min read
Beyond the Dose: Why Some GLP-1s Fall Short & What It Means
A groundbreaking Stanford study reveals a genetic reason why approximately 10% of individuals don't respond as expected to GLP-1 receptor agonists, impacting treatments for diabetes and weight loss.
7 min read
Pfizer's Berobenatide: A New Monthly GLP-1 for Weight Loss?
Pfizer's investigational GLP-1 receptor agonist, berobenatide, has shown promising results in Phase 2b trials for weight loss. This article delves into the data, its implications for obesity treatment, and what it means for Pfizer's investment outlook.
7 min read
Wegovy, Mounjaro & Your Libido: How GLP-1s Reshape Desire
GLP-1 medications have transformed weight management and diabetes care, but their effects extend beyond the scale. Many users report surprising changes to their libido and sexual function. This article delves into why these powerful drugs can either boost or dampen your sex drive, offering insights from leading medical experts.
9 min read
Wegovy and Zepbound on Medicare: What the $50 Co-Pay Means for Your Health
A new federal agreement could lower the cost of popular weight-loss medications like Wegovy and Zepbound to $50 per month for eligible Medicare beneficiaries. Here is what you need to know about eligibility and clinical impact.
7 min read
Semaglutide and Pregnancy: Understanding New Risks and Weight Rebound
A recent national database study reveals significant obstetric risks associated with semaglutide exposure before and during pregnancy, highlighting the importance of the weight rebound effect.
7 min read
GLP-1 Drugs & Your Knees: New Research on Joint Health
Discover how GLP-1 medications, known for weight loss, may also significantly reduce the need for knee replacement surgery. This article delves into the latest research and its implications for joint health.
7 min read
Ozempic Safety: How to Verify Batch Numbers and Avoid Counterfeit Drugs
With the surge in demand for weight loss and diabetes medications, counterfeit drugs have become a critical safety concern. This guide details how to verify Ozempic batch numbers and protect your health.
7 min read
Ozempic Weight Loss: Why Your Body Needs One More Key Step
Ozempic is a household name, but experts warn it isn't a magic bullet. Dr. Shilpa Verma discusses the essential lifestyle component required for sustainable weight loss.
6 min read
Beyond the Needle: Why Wegovy Alone Can't Cure New Zealand's Obesity Crisis
As New Zealand considers public funding for Wegovy, experts warn that medication alone cannot solve the obesity epidemic driven by complex environmental and social factors.
8 min read
Glenmark's Semaglutide Launch: What It Means for Global Weight Loss Access
Glenmark Pharmaceuticals outlines an ambitious FY27 growth strategy, highlighting significant expansion in the GLP-1 segment with GLIPIQ. Discover how this impacts global access to Semaglutide and weight loss therapies.
7 min read
Ozempic and the Shift: Real Data on America's Obesity Rates
New data from EPIC Research highlights a correlation between rising GLP-1 prescriptions and a modest decline in US obesity rates, offering hope amidst ongoing challenges.
7 min read
Wegovy Pill Arrives: A New Era for Oral Weight Management in the UAE
Novo Nordisk's revolutionary Wegovy pill (oral semaglutide) is set to transform weight management in the UAE. Discover the details of its early access launch, clinical benefits, and how it integrates into advanced care pathways.
7 min read
Beyond Weight Loss: The Expanding Horizon of GLP-1 Therapies
GLP-1 agonists, famously known for Ozempic and Wegovy, are making waves beyond their initial indications. While weight loss and diabetes management remain key, researchers are uncovering a broader therapeutic potential for these powerful peptide therapies.
8 min read
Ozempic & Beyond: Are GLP-1s Shifting America's Obesity Battle?
Once a distant rumor, the idea of widespread obesity in America is now being challenged by a new wave of medications. Discover how GLP-1 drugs are changing the landscape of weight management and what it means for public health.
8 min read
GLP-1 Therapies: Australia's New Blueprint for Obesity and Heart Health
Australia has released a groundbreaking clinical consensus statement on obesity and cardiovascular disease (CVD), marking a pivotal moment in medical practice. This new guidance places GLP-1 receptor agonists—a class of medications including semaglutide and tirzepatide—at the forefront of treatment strategies, offering clinicians a clear, practical pathway for improving patient outcomes.
6 min read
Beyond the Injection: GLP-1s, Diet, and the Future of Weight Management
GLP-1 receptor agonists have revolutionized obesity and diabetes management, offering unprecedented appetite control. However, as adoption surges, especially in markets like India, medical experts emphasize that these powerful tools must be integrated with fundamental lifestyle changes and supportive public health infrastructure to ensure lasting success.
6 min read
Beyond 'Ozempic Breath': The Hidden Nutrient Deficiencies
While GLP-1 medications are celebrated for their effectiveness in managing type 2 diabetes and aiding weight loss, a growing concern is the potential for nutrient deficiencies. This article delves into the science behind this 'under-the-radar' side effect and what proactive steps you can take.
7 min read
Beyond Weight Loss: Do GLP-1 Drugs Impact Mental Health?
New research is exploring the surprising potential of GLP-1 receptor agonists, known for their role in diabetes and weight management, to also influence mental well-being. This article delves into the latest findings and what they mean for patients.
7 min read
Beyond Appetite: How GLP-1 Drugs May Be Rewiring the Human Brain
GLP-1 receptor agonists, initially celebrated for revolutionizing diabetes and weight management, are now at the center of an unplanned, massive neuroscience experiment. Emerging data suggests these powerful medications are doing more than just regulating metabolism; they appear to be structurally and functionally altering key brain systems.
7 min read